Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting
Stock Information for Medicenna Therapeutics Corp.
Loading
Please wait while we load your information from QuoteMedia.